Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Stock Rating Lowered by Wall Street Zen

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Saturday.

Other analysts have also issued reports about the company. The Goldman Sachs Group upgraded Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Thursday, June 5th. Kepler Capital Markets upgraded Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a research report on Wednesday, June 11th. Finally, Hsbc Global Res upgraded Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, June 11th. Two analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy”.

Bayer Aktiengesellschaft Price Performance

Shares of BAYRY stock opened at $7.67 on Friday. The stock’s fifty day moving average is $7.20 and its 200-day moving average is $6.22. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.79 and a current ratio of 1.25. The stock has a market capitalization of $30.14 billion, a PE ratio of -8.34 and a beta of 0.86. Bayer Aktiengesellschaft has a 52 week low of $4.79 and a 52 week high of $8.58.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last posted its quarterly earnings results on Tuesday, May 13th. The company reported $0.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.63 by $0.02. The business had revenue of $15.27 billion for the quarter, compared to analysts’ expectations of $13.39 billion. Bayer Aktiengesellschaft had a positive return on equity of 13.94% and a negative net margin of 7.26%. Equities research analysts expect that Bayer Aktiengesellschaft will post 1.31 EPS for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.